|
EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Ensures Business Continuity After Cyber-Attack 25.02.2025 / 09:59 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group’s business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another. As of this week, all essential core systems are back in operation. In some cases, temporary solutions have been implemented to offer all business partners the full range of services again. “We have temporarily converted some digital processes to manual processes in recent weeks. However, our production continues, and we can supply our customers,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. Eckert & Ziegler remains committed to upholding the highest standards of safety and integrity and thanks its patients, customers and partners for their patience and understanding during this incident. “I would like to thank everyone involved for their tremendous efforts during the last few weeks. A special thanks goes to our colleagues in IT, who are giving their best to get us back up and running as quickly as possible. We kindly ask our business partners to continue to be understanding and patient if there are still temporary delays or restrictions in communication at the moment,” added Dr. Harald Hasselmann. The Executive Board currently does not expect any significant adverse effects on the business. Contact: 25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Sickle cell cures are coming. African children can’t be left behind
The treatment of sickle cell disease is on the cusp of a historic breakthrough, with makers of two gene-based treatments for the debilitating blood disorder
July 12, 2023